Rural Response to the Opioid Crisis – Resources
Selected recent or important resources focusing on Rural Response to the Opioid Crisis.
The Opioid Epidemic in Rural Communities: Can Telehealth Increase Access to Medication for Opioid Use Disorder and Offset Barriers to Care?
Examines the impact of telehealth on access to medication for opioid use disorder (MOUD) and substance use disorder (SUD) and opioid use disorder (OUD) treatment. Utilizes data from the Rural Communities Opioid Response Program's (RCORP) consortia, the National Survey of Drug Use and Health (NSDUH), and the U.S. Census Bureau's American Community Survey (ACS) to analyze access to MOUD and rates of telehealth use for rural consortia. Discusses potential barriers and factors impacting telehealth implementation for SUD and OUD care.
Author(s): Kathleen Meyers, Shannon Herman, Heather Schuler, et al.
Citation: Drug and Alcohol Dependence, 271, 112628
Date: 06/2025
view details
Examines the impact of telehealth on access to medication for opioid use disorder (MOUD) and substance use disorder (SUD) and opioid use disorder (OUD) treatment. Utilizes data from the Rural Communities Opioid Response Program's (RCORP) consortia, the National Survey of Drug Use and Health (NSDUH), and the U.S. Census Bureau's American Community Survey (ACS) to analyze access to MOUD and rates of telehealth use for rural consortia. Discusses potential barriers and factors impacting telehealth implementation for SUD and OUD care.
Author(s): Kathleen Meyers, Shannon Herman, Heather Schuler, et al.
Citation: Drug and Alcohol Dependence, 271, 112628
Date: 06/2025
view details
Effects of Using Different Rural Measurements on Estimates of Hospitalizations for Depression and Substance Use
Explores how using different rural measurements can affect estimates of hospitalization rates for behavioral health conditions. Highlights how Rural-Urban Commuting Areas (RUCA) codes, Core-Based Statistical Areas (CBSA), Urban-Rural Category 4 (URCategory4), and Rural-Urban Continuum Codes (RUCC) affect hospitalization estimates. Discusses the consequences these difference can have on policy.
Author(s): Robin Danek, Justin Blackburn, Marion Greene, et al.
Citation: BMC Health Services Research, 25, 818
Date: 06/2025
view details
Explores how using different rural measurements can affect estimates of hospitalization rates for behavioral health conditions. Highlights how Rural-Urban Commuting Areas (RUCA) codes, Core-Based Statistical Areas (CBSA), Urban-Rural Category 4 (URCategory4), and Rural-Urban Continuum Codes (RUCC) affect hospitalization estimates. Discusses the consequences these difference can have on policy.
Author(s): Robin Danek, Justin Blackburn, Marion Greene, et al.
Citation: BMC Health Services Research, 25, 818
Date: 06/2025
view details
Evaluation of the Maternal Opioid Misuse (MOM) Model: Fourth Annual Report (Implementation Year 3)
Provides an overview of the Maternal Opioid Misuse Model, which provides evidence-based integrated care and care coordination for pregnant and postpartum Medicaid beneficiaries with opioid use disorder (OUD). Describes activities MOM Model awardees undertook during the MOM Model's second implementation year, July 1, 2023–June 30, 2024, and summarizes qualitative and beneficiary-level process data findings by state awardee. Discusses barriers pregnant and postpartum women with OUD face in accessing high-quality, continuous care, specifically in rural areas.
Additional links: Findings at a Glance
Date: 06/2025
Sponsoring organizations: Centers for Medicare & Medicaid Services, Westat
view details
Provides an overview of the Maternal Opioid Misuse Model, which provides evidence-based integrated care and care coordination for pregnant and postpartum Medicaid beneficiaries with opioid use disorder (OUD). Describes activities MOM Model awardees undertook during the MOM Model's second implementation year, July 1, 2023–June 30, 2024, and summarizes qualitative and beneficiary-level process data findings by state awardee. Discusses barriers pregnant and postpartum women with OUD face in accessing high-quality, continuous care, specifically in rural areas.
Additional links: Findings at a Glance
Date: 06/2025
Sponsoring organizations: Centers for Medicare & Medicaid Services, Westat
view details
Barriers and Facilitators to Scaling up Medications for Opioid Use Disorder in Kentucky: Qualitative Perspectives of Treatment Organization Staff
Examines perspectives from substance use treatment program staff related to the barriers and facilitators of medications for opioid use disorder (MOUD) utilization. Provides qualitative feedback data from agency staff in Kentucky and discusses organizational, patient, and community factors that impact MOUD utilization. Includes perspectives from rural areas.
Author(s): Hannah K. Knudsen, Shaquita Andrews-Higgins, Sandra Back-Haddix, et al.
Citation: Substance Abuse Treatment, Prevention, and Policy, 20, 15
Date: 04/2025
view details
Examines perspectives from substance use treatment program staff related to the barriers and facilitators of medications for opioid use disorder (MOUD) utilization. Provides qualitative feedback data from agency staff in Kentucky and discusses organizational, patient, and community factors that impact MOUD utilization. Includes perspectives from rural areas.
Author(s): Hannah K. Knudsen, Shaquita Andrews-Higgins, Sandra Back-Haddix, et al.
Citation: Substance Abuse Treatment, Prevention, and Policy, 20, 15
Date: 04/2025
view details
Medicare Beneficiary Receipt of Methadone by Drive Time to Opioid Treatment Programs
Examines availability of methadone at opioid treatment programs for Medicare beneficiaries who have been diagnosed with an opioid use disorder. Utilizes data from 640,706 Medicare beneficiaries and analyzes their respective drive time to a treatment facility as well as receipt of methadone treatment. Includes U.S. map showing locations of opioid treatment programs and rural versus urban comparisons of patient drive times.
Author(s): Jonathan Cantor, Helin G. Hernandez, Aaron Kofner, et al.
Citation: JAMA Network Open, 8(4), e253099
Date: 04/2025
view details
Examines availability of methadone at opioid treatment programs for Medicare beneficiaries who have been diagnosed with an opioid use disorder. Utilizes data from 640,706 Medicare beneficiaries and analyzes their respective drive time to a treatment facility as well as receipt of methadone treatment. Includes U.S. map showing locations of opioid treatment programs and rural versus urban comparisons of patient drive times.
Author(s): Jonathan Cantor, Helin G. Hernandez, Aaron Kofner, et al.
Citation: JAMA Network Open, 8(4), e253099
Date: 04/2025
view details
The Rural and Urban Supply of Clinicians With a DEA Waiver to Prescribe Buprenorphine in 2022 Prior to the Elimination of the Waiver Requirement
Report explores the differences in rates of clinicians with DEA waivers to prescribe buprenorphine in 2022 in rural versus urban counties. Highlights the rural gaps in access to buprenorphine to treat opioid use disorder prior to the elimination of the DEA waiver requirement in 2023. Provides rural, urban, and regional comparisons.
Date: 04/2025
Sponsoring organization: WWAMI Rural Health Research Center
view details
Report explores the differences in rates of clinicians with DEA waivers to prescribe buprenorphine in 2022 in rural versus urban counties. Highlights the rural gaps in access to buprenorphine to treat opioid use disorder prior to the elimination of the DEA waiver requirement in 2023. Provides rural, urban, and regional comparisons.
Date: 04/2025
Sponsoring organization: WWAMI Rural Health Research Center
view details
Delivering Medications for Opioid Use Disorder in Primary Care: Environmental Scan
Report provides a literature review and interviews with key informants to outline the opioid use disorder (OUD) treatment environment and make policy recommendations. Discusses how changes to regulations have affected access to medications for opioid use disorder (MOUD), how the opioid use environment has changed, and what models and evidence-based tools exist to facilitate OUD treatment, among other issues.
Author(s): Collette Sosnowy, Danielle Durant, Garrett Moran, et al.
Date: 03/2025
Sponsoring organization: Agency for Healthcare Research and Quality
view details
Report provides a literature review and interviews with key informants to outline the opioid use disorder (OUD) treatment environment and make policy recommendations. Discusses how changes to regulations have affected access to medications for opioid use disorder (MOUD), how the opioid use environment has changed, and what models and evidence-based tools exist to facilitate OUD treatment, among other issues.
Author(s): Collette Sosnowy, Danielle Durant, Garrett Moran, et al.
Date: 03/2025
Sponsoring organization: Agency for Healthcare Research and Quality
view details
Epidemiology of 911 Calls for Opioid Overdose in Nogales, Arizona
Presents a study reviewing the 911 calls pertaining to opioid overdose in the Nogales, AZ area. Details the prehospital care received in the rural, borderland community and evaluates EMS's adherence to naloxone distribution protocol.
Author(s): Melody Glenn, Darien Stratton, Keith Primeau, Amber Rice
Citation: Western Journal of Emergency Medicine: Integrating Emergency Care with Population Health, 26(3)
Date: 03/2025
view details
Presents a study reviewing the 911 calls pertaining to opioid overdose in the Nogales, AZ area. Details the prehospital care received in the rural, borderland community and evaluates EMS's adherence to naloxone distribution protocol.
Author(s): Melody Glenn, Darien Stratton, Keith Primeau, Amber Rice
Citation: Western Journal of Emergency Medicine: Integrating Emergency Care with Population Health, 26(3)
Date: 03/2025
view details
Comparative Effectiveness of Buprenorphine Adherence with Telemedicine Versus In-Person for Rural and Urban Patients
Compares adherence to buprenorphine for opioid use disorder in telemedicine versus in-person healthcare in rural and urban populations. Utilizes 2017–2022 data from 511 adults and compares 3,302 in-person and 519 telemedicine visits, with breakdowns according to patient characteristics, adherence, gaps in treatment, and rural versus urban location. Discusses changing legislative requirements related to buprenorphine treatment and the potential impact on rural populations.
Author(s): Thomas J. Reese, Nana Addo Padi-Adjirackor, Kevin N. Griffith, et al.
Citation: Journal of the American Pharmacists Association, 65(2), 102318
Date: 03/2025
view details
Compares adherence to buprenorphine for opioid use disorder in telemedicine versus in-person healthcare in rural and urban populations. Utilizes 2017–2022 data from 511 adults and compares 3,302 in-person and 519 telemedicine visits, with breakdowns according to patient characteristics, adherence, gaps in treatment, and rural versus urban location. Discusses changing legislative requirements related to buprenorphine treatment and the potential impact on rural populations.
Author(s): Thomas J. Reese, Nana Addo Padi-Adjirackor, Kevin N. Griffith, et al.
Citation: Journal of the American Pharmacists Association, 65(2), 102318
Date: 03/2025
view details
Social Network Barriers to Extended-Release Naltrexone Within Rural Appalachia: Perspectives from Justice-Involved Clients and Clinicians
Presents a study on the role of family, friends, and clinicians can play in influencing naltrexone treatment uptake of people with opioid use disorder (POUD) who are incarcerated in Appalachia. Bases findings on interviews with clinicians and breaks down data by sociodemographic characteristics, substance use, and social network composition, among other measures.
Author(s): Amanda M. Bunting, Carrie B. Oser, Marisa Booty, et al.
Citation: Substance Use & Misuse, 60(5), 758-765
Date: 01/2025
view details
Presents a study on the role of family, friends, and clinicians can play in influencing naltrexone treatment uptake of people with opioid use disorder (POUD) who are incarcerated in Appalachia. Bases findings on interviews with clinicians and breaks down data by sociodemographic characteristics, substance use, and social network composition, among other measures.
Author(s): Amanda M. Bunting, Carrie B. Oser, Marisa Booty, et al.
Citation: Substance Use & Misuse, 60(5), 758-765
Date: 01/2025
view details
Additional resources are available related to this guide. See the full list of resources by topic for: